Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Purple Biotech (PPBT)
NASDAQ:PPBT
Holding PPBT?
Track your performance easily
PPBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $1.80
Previous Close$0.4
Volume82.17K
Average Volume (3M)312.28K
Market Cap
$12.19M
Enterprise Value-$2.78M
Total Cash (Recent Filing)$15.41M
Total Debt (Recent Filing)$351.00K
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Nov 05, 2024EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding31,320,000
10 Day Avg. Volume288,786
30 Day Avg. Volume312,284
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$8.00Price Target Upside8.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Purple Biotech News
PremiumCompany Announcements
Purple Biotech Reveals Optimistic Cancer Treatment Data
PremiumCompany Announcements
Purple Biotech Announces ADS Ratio Change
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataThe company presented positive interim data from the Nal-IRI cohort at ASCO 2024.
Safety ProfileThe therapy was generally well-tolerated with no concerning adverse events observed.
Therapy EfficacyConsistent benefit noted across all endpoints measured in the CM24 treatment arm compared to chemotherapy alone.
Bears Say
Clinical Trial DataThe gem/nab-paclitaxel cohort was impacted by informative censoring of the control arm which led to an imbalance in the number of patients in the active and control arms, which made this cohort of patients unsuitable for analysis.
Financial ResourcesNT219 is Phase 2 ready though company likely needs additional resources to advance this program.
Safety ConcernsThere was a higher number of Grade 3+ treatment-emergent adverse events rate of 94% compared to 67% for control, which included higher rates of diarrhea and fatigue.
---
Ownership Overview
0.00%
Insiders
0.04% Mutual Funds
5.01% Other Institutional Investors
94.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $0.30 and its highest was $1.80 in the past 12 months.
What is Purple Biotech’s market cap?
Currently, no data Available
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 16, 2024. The company reported -$1.8 earnings per share for the quarter, beating the consensus estimate of -$2.3 by $0.5.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -$1.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 32,384,514 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$1.8 in its last earnings report, beating expectations of -$2.3. Following the earnings report the stock price went up 2.778%.
Which hedge fund is a major shareholder of Purple Biotech?
Among the largest hedge funds holding Purple Biotech’s share is Fisher Asset Management LLC. It holds Purple Biotech’s shares valued at N/A.
---
Purple Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (8.55% Upside)
$8.00 (8.55% Upside)
Hedge Fund Trend
Decreased
By 32.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.9%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.13%
12-Months-Change
Fundamentals
Return on Equity
-44.58%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Purple Biotech
Kitov Pharma Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.
---
PPBT Stock 12 Month Forecast
Average Price Target
$8.00
▲(8.55% Upside)
Technical Analysis
Best Analysts Covering PPBT
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-36.54%
reiterated a buy rating last month
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -36.54% per trade.
---